TransMedics (TMDX) is a publicly traded Healthcare sector company. As of October 13, 2026, TMDX trades at $77.97 with a market cap of $2.70B and a P/E ratio of 17.68. TMDX moved +0.39% today. Year to date, TMDX is -35.74%; over the trailing twelve months it is -27.14%. Its 52-week range spans $60.11 to $156.00. Analyst consensus is buy with an average price target of $97.56. Rallies surfaces TMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for TMDX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $77.97 |
| Market Cap | $2.70B |
| P/E Ratio | 17.68 |
| EPS | $4.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $156.00 |
| 52-Week Low | $60.11 |
| Volume | 410.90K |
| Avg Volume | 0 |
| Revenue (TTM) | $668.47M |
| Net Income | $151.70M |
| Gross Margin | 58.69% |
11 analysts cover TMDX: 0 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $97.56.